J&J Files Antitrust Complaint Against Amgen For Aranesp Pricing Practice
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen's bundling of rebates for Aranesp, Neulasta and Neupogen have unfairly increased the anemia therapy's market share, the complaint alleges.
You may also be interested in...
Procrit Critical Care Label Expansion Could Fuel Franchise Sales, J&J Says
Johnson & Johnson remains committed to the anemia agent despite failing to return the franchise to growth in 2005.
Procrit Critical Care Label Expansion Could Fuel Franchise Sales, J&J Says
Johnson & Johnson remains committed to the anemia agent despite failing to return the franchise to growth in 2005.
J&J Expects EPO Pricing Injunction Ruling In Early 2006
If the court fails to grant a preliminary injunction against Amgen, "tremendous price pressure" will be reinjected into the EPO market, the Procrit marketer tells analysts.